Cargando…

Radiotherapeutic treatment options for oligotopic malignant liver lesions

BACKGROUND: Several radiotherapeutic approaches for patients with oligotopic malignant liver lesions unfit for surgical resection exist. The most advanced competitive techniques are high-dose-rate (HDR) brachytherapy, Cyberknife, volume-modulated-arc therapy (VMAT) and Tomotherapy. We evaluated the...

Descripción completa

Detalles Bibliográficos
Autores principales: Wust, Peter, Beck, Marcus, Dabrowski, Robert, Neumann, Oliver, Zschaeck, Sebastian, Kaul, David, Modest, Dominik P., Stromberger, Carmen, Gebauer, Bernhard, Ghadjar, Pirus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7970808/
https://www.ncbi.nlm.nih.gov/pubmed/33726751
http://dx.doi.org/10.1186/s13014-021-01779-5
_version_ 1783666485771632640
author Wust, Peter
Beck, Marcus
Dabrowski, Robert
Neumann, Oliver
Zschaeck, Sebastian
Kaul, David
Modest, Dominik P.
Stromberger, Carmen
Gebauer, Bernhard
Ghadjar, Pirus
author_facet Wust, Peter
Beck, Marcus
Dabrowski, Robert
Neumann, Oliver
Zschaeck, Sebastian
Kaul, David
Modest, Dominik P.
Stromberger, Carmen
Gebauer, Bernhard
Ghadjar, Pirus
author_sort Wust, Peter
collection PubMed
description BACKGROUND: Several radiotherapeutic approaches for patients with oligotopic malignant liver lesions unfit for surgical resection exist. The most advanced competitive techniques are high-dose-rate (HDR) brachytherapy, Cyberknife, volume-modulated-arc therapy (VMAT) and Tomotherapy. We evaluated the optimal technique by a planning study for a single ablative dose with different lesion sizes. METHODS: We compared dose distributions of HDR-brachytherapy with stereotactic ablative radiotherapy using the Cyberknife, VMAT or Tomotherapy. Tumor-control-probabilities (TCP), normal-tissue-complication-probabilities (NTCP) were determined in a theoretical framework applying a single dose of 20 Gy (demanding 95% coverage) for intrahepatic lesions of 1–5 cm in size. We evaluated therapeutic ratios by TCP (mean dose in the lesion) relative to high-dose (conformality) or low-dose liver exposition in dependency on the lesion size for each technique. In addition, we considered treatment times and accuracy (clinical target volume vs planning target volume). RESULTS: HDR-brachtherapy has the highest therapeutic ratios with respect to high-dose as well as low-dose liver exposition even for extended lesions, and the Cyberknife being suited second best. However, for lesions ≥ 3 cm diameter the therapeutic ratios of all ablative techniques are increasingly converging, and better tolerance and shorter treatment times of noninvasive external techniques become more important. On the other hand, mean tumor doses of HDR-brachytherapy of near 60 Gy are unattainable by the other techniques gaining only 22–34 Gy, and the conformality of HDR-brachytherapy is still rather good for lesions ≥ 3 cm diameter. CONCLUSIONS: HDR-brachytherapy is by far the most effective technique to treat intrahepatic lesions by a single fraction, but sparing of the surroundings declines with increasing lesion size and approaches the benchmarks of external beam radiosurgery techniques. External beam radiotherapy has the advantage to use suitable fractionation schedules.
format Online
Article
Text
id pubmed-7970808
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-79708082021-03-19 Radiotherapeutic treatment options for oligotopic malignant liver lesions Wust, Peter Beck, Marcus Dabrowski, Robert Neumann, Oliver Zschaeck, Sebastian Kaul, David Modest, Dominik P. Stromberger, Carmen Gebauer, Bernhard Ghadjar, Pirus Radiat Oncol Research BACKGROUND: Several radiotherapeutic approaches for patients with oligotopic malignant liver lesions unfit for surgical resection exist. The most advanced competitive techniques are high-dose-rate (HDR) brachytherapy, Cyberknife, volume-modulated-arc therapy (VMAT) and Tomotherapy. We evaluated the optimal technique by a planning study for a single ablative dose with different lesion sizes. METHODS: We compared dose distributions of HDR-brachytherapy with stereotactic ablative radiotherapy using the Cyberknife, VMAT or Tomotherapy. Tumor-control-probabilities (TCP), normal-tissue-complication-probabilities (NTCP) were determined in a theoretical framework applying a single dose of 20 Gy (demanding 95% coverage) for intrahepatic lesions of 1–5 cm in size. We evaluated therapeutic ratios by TCP (mean dose in the lesion) relative to high-dose (conformality) or low-dose liver exposition in dependency on the lesion size for each technique. In addition, we considered treatment times and accuracy (clinical target volume vs planning target volume). RESULTS: HDR-brachtherapy has the highest therapeutic ratios with respect to high-dose as well as low-dose liver exposition even for extended lesions, and the Cyberknife being suited second best. However, for lesions ≥ 3 cm diameter the therapeutic ratios of all ablative techniques are increasingly converging, and better tolerance and shorter treatment times of noninvasive external techniques become more important. On the other hand, mean tumor doses of HDR-brachytherapy of near 60 Gy are unattainable by the other techniques gaining only 22–34 Gy, and the conformality of HDR-brachytherapy is still rather good for lesions ≥ 3 cm diameter. CONCLUSIONS: HDR-brachytherapy is by far the most effective technique to treat intrahepatic lesions by a single fraction, but sparing of the surroundings declines with increasing lesion size and approaches the benchmarks of external beam radiosurgery techniques. External beam radiotherapy has the advantage to use suitable fractionation schedules. BioMed Central 2021-03-16 /pmc/articles/PMC7970808/ /pubmed/33726751 http://dx.doi.org/10.1186/s13014-021-01779-5 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Wust, Peter
Beck, Marcus
Dabrowski, Robert
Neumann, Oliver
Zschaeck, Sebastian
Kaul, David
Modest, Dominik P.
Stromberger, Carmen
Gebauer, Bernhard
Ghadjar, Pirus
Radiotherapeutic treatment options for oligotopic malignant liver lesions
title Radiotherapeutic treatment options for oligotopic malignant liver lesions
title_full Radiotherapeutic treatment options for oligotopic malignant liver lesions
title_fullStr Radiotherapeutic treatment options for oligotopic malignant liver lesions
title_full_unstemmed Radiotherapeutic treatment options for oligotopic malignant liver lesions
title_short Radiotherapeutic treatment options for oligotopic malignant liver lesions
title_sort radiotherapeutic treatment options for oligotopic malignant liver lesions
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7970808/
https://www.ncbi.nlm.nih.gov/pubmed/33726751
http://dx.doi.org/10.1186/s13014-021-01779-5
work_keys_str_mv AT wustpeter radiotherapeutictreatmentoptionsforoligotopicmalignantliverlesions
AT beckmarcus radiotherapeutictreatmentoptionsforoligotopicmalignantliverlesions
AT dabrowskirobert radiotherapeutictreatmentoptionsforoligotopicmalignantliverlesions
AT neumannoliver radiotherapeutictreatmentoptionsforoligotopicmalignantliverlesions
AT zschaecksebastian radiotherapeutictreatmentoptionsforoligotopicmalignantliverlesions
AT kauldavid radiotherapeutictreatmentoptionsforoligotopicmalignantliverlesions
AT modestdominikp radiotherapeutictreatmentoptionsforoligotopicmalignantliverlesions
AT strombergercarmen radiotherapeutictreatmentoptionsforoligotopicmalignantliverlesions
AT gebauerbernhard radiotherapeutictreatmentoptionsforoligotopicmalignantliverlesions
AT ghadjarpirus radiotherapeutictreatmentoptionsforoligotopicmalignantliverlesions